Whole-Body and Microenvironmental Localization of Radium-223 in Naïve and Mouse Models of Prostate Cancer Metastasis.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

Bone-metastatic, castration-resistant prostate cancer (bmCRPC) represents a lethal stage of the most common noncutaneous cancer in men. The recent introduction of Radium-223 dichloride, a bone-seeking alpha particle (α)-emitting radiopharmaceutical, demonstrates statistically significant survival benefit and palliative effect for bmCRPC patients. Clinical results have established safety and efficacy, yet questions remain regarding pharmacodynamics and dosing for optimized patient benefit.

Detaljer

Författare
  • Diane S Abou
  • David Ulmert
  • Michele Doucet
  • Robert F Hobbs
  • Ryan C Riddle
  • Daniel L J Thorek
Enheter & grupper
Externa organisationer
  • Johns Hopkins University
  • Memorial Sloan-Kettering Cancer Center
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Cancer och onkologi
Originalspråkengelska
Artikelnummerdjv380
TidskriftJournal of the National Cancer Institute
Volym108
Utgåva nummer5
StatusPublished - 2016
PublikationskategoriForskning
Peer review utfördJa